MMCM
VRTX icon

Murphy & Mullick Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Murphy & Mullick Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.41M Sell
3,148
-38
-1% -$17.7K 1.04% 22
2025
Q4 		$1.44M Sell
3,186
-38
-1% -$16.4K 1.04% 23
2025
Q3 		$1.26M Sell
3,224
-30
-0.9% -$12.5K 0.94% 24
2025
Q2 		$1.49M Sell
3,254
-6
-0.2% -$2.77K 1.21% 20
2025
Q1 		$1.58M Hold
3,260
– – 1.53% 13
2024
Q4 		$1.31M Buy
+3,260
New +$1.51M 1.21% 18

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Murphy & Mullick Capital Management's VRTX Position: Q1 2026 in Review

Murphy & Mullick Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 1.2% in Q1 2026, selling an estimated $17.7K and leaving 3,148 shares worth $1.41M. The position accounts for 1.04% of the portfolio, ranked #22.

Murphy & Mullick Capital Management first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.58M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Murphy & Mullick Capital Management held 3,148 shares of Vertex Pharmaceuticals worth $1.41M as of Q1 2026.
  • Murphy & Mullick Capital Management sold 38 Vertex Pharmaceuticals shares in Q1 2026, an estimated $17.7K.
  • Vertex Pharmaceuticals made up 1.04% of Murphy & Mullick Capital Management's portfolio in Q1 2026, its #22 holding.
  • Murphy & Mullick Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Murphy & Mullick Capital Management's Vertex Pharmaceuticals position peaked at $1.58M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.